Mindset Pharma says InterVivo releases first data set for jointly developed Cooperative Psychedelics Evaluation Platform program

Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF), a biotechnology company developing psychedelic medicines and technologies, noted that InterVivo Solutions (IVS) had released the first data set as part of its jointly developed advanced Cooperative Psychedelics Evaluation Platform (COPE) program.  The program, launched in March, aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT amongst others.  Preliminary data focused on psilocybin/psilocin and shows that clinical exposure levels reported in humans correlate to exposure and efficacy measures observed in mice - validating the predictive value of IVS's selected behavioural assays and animal models. Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to IVS' behavioral models, said the company. READ: Mindset Pharma selects next-generation psychedelic compound MSP-1014 as its lead clinical candidate As part of the COPE program, IVS is immediately making available its Bioanalytical Platform to its global client base, offering pre-developed and qualified LC-MS analytical protocols for a growing list of known psychedelics and related chemical compounds, including their active metabolites, added the firm. Sponsors will be able to submit their in-life samples for analysis at InterVivo's bioanalytical lab, in the Greater Toronto Area. Lead investigators for the platform are Dr Ines de Lannoy and Dr Lilia Magomedova, who are overseeing its development and application to profiling the pharmacokinetics properties of the selected psychedelic molecules. In a statement, Dr Guy Higgins, who is the Chief Scientific Officer at IVS and a Scientific Advisory Board member at Mindset, said: "On this day, 78 years ago, the first woman in history experienced the effects of LSD. Susi Ramstein was a lab assistant with Albert Hoffman at Sandoz labs in Basel where LSD was first synthesised.” “Despite the widespread interest in the therapeutic potential of psychedelics, there is relatively little preclinical data relating their efficacy/safety profiles to plasma and CNS exposures, and PK properties. Developing this knowledge base for psychedelics such as LSD and psilocybin, currently being evaluated in the clinic, will undoubtedly help the value assessment of newer psychedelics in development.” Meanwhile, Mindset Pharma CEO James Lanthier said the companies are developing the “tools and metrics” with which the industry will determine success and “we're doing it faster than anyone, thanks to the expertise at InterVivo.” “A founding principle of Mindset has been to continuously assemble comprehensive data on both our own novel drugs, as well as reference compounds, to guide and inform our scientific decision making. The COPE program data sets have been carefully built in partnership with InterVivo’s industry-leading pre-clinical scientific team. We believe that this data will be of great use to in the broader psychedelic/CNS space."  “We're delighted with the progress and insights driving the efficiency of our drug development engine, and are eager to translate that knowledge into real value for the mental health crisis we aim to solve,” added Lanthier. Lanthier also acknowledged the contributions of the firm's research partners and in particular, "the many Women of Science who have made so many unsung contributions to humanity's understanding of nature and medicine.” Detailed information on the COPE Benchmark data set and the Bioanalytical Platform is being made available immediately to IVS sponsors, said the company. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive